ke nalu uluhlu lweenkampani eziphezulu zeBiotech eJamani ezihlelwe ngokwengeniso epheleleyo.
| S / N | Igama leKhampani | Iyonke iNgeniso (FY) | Inani le abasebenzi |
| 1 | Morphosys Ag | $ 401 yezigidi | 615 |
| 2 | Ubuchopho beBiotec Na | $ 45 yezigidi | 279 |
| 3 | Formycon Ag | $ 42 yezigidi | 131 |
| 4 | Biofrontera Ag Na | $ 37 yezigidi | 149 |
| 5 | Vita 34 Ag Na | $ 25 yezigidi | 116 |
| 6 | Heidelberg Pharma Ag | $ 10 yezigidi | 84 |
| 7 | Medigene Ag Na | $ 10 yezigidi | 121 |
| 8 | 4Sc Ag Inh. | $ 3 yezigidi | 48 |
Morphosys Ag
I-MorphoSys AG isebenza njengenkampani ye-biopharmaceutical yenqanaba lorhwebo. Inkampani igxile ekufumaneni, ekuphuhliseni, nasekuhanjisweni kwamayeza omhlaza aqalayo. IMorphoSys inceda abathengi kwihlabathi liphela.
BRAIN Biotech AG
I-BRAIN Biotech AG yinkampani yetekhnoloji, ebandakanyeka kuphuhliso kunye norhwebo lwe-bioactives, iikhompawundi zendalo, kunye nee-enzymes zobunikazi. Isebenza ngeBioScience kunye neBioIndustrial segment.
Icandelo le-BioScience lisebenza kwii-enzymes kunye ne-microorganisms yokusebenza; kwaye usebenzisana namaqabane ezoshishino. Icandelo le-BioIndustrial lijongene nemveliso yezinto eziphilayo kunye namashishini ezinto zokuthambisa. Inkampani yasekwa nguHolger Zinke, uJüngen Eck, kunye noHans Günter Gassen ngoSeptemba 22, 1993 kwaye ikomkhulu lakhe lihlala eZwingenberg, eJamani.
Formycon
I-Formycon ngumphuhlisi okhokelayo, ozimeleyo wamayeza e-biopharmaceutical akumgangatho ophezulu, ngakumbi ii-biosimilars. Inkampani igxile kunyango lwe-ophthalmology, i-immunology kunye nezinye izifo eziphambili ezingapheliyo, ezigubungela lonke ikhonkco lexabiso ukusuka kuphuhliso lobugcisa ukuya kwisigaba se-III seklinikhi kunye nokulungiswa kweedosi zokuvunywa kwentengiso.
Ngebiosimilars zayo, iFormycon yenza igalelo elikhulu ekuboneleleni ngezigulane ezininzi kangangoko ngokufikelela kumayeza abalulekileyo nafikelelekayo. Ngoku iFormycon ineebhayosimila ezintandathu kuphuhliso. Ngokusekwe kumava ayo abanzi kuphuhliso lwamachiza e-biopharmaceutical, inkampani ikwasebenza ekuphuhliseni ichiza le-COVID-19 FYB207.
Biofrontera Ag Na
I-Biofrontera AG yinkampani ye-biopharmaceutical ekhethekileyo ekuphuhliseni nasekuthengisweni kwamachiza e-dermatological kunye nezithambiso zonyango. Inkampani esekwe eLeverkusen iphuhlisa kwaye ithengise iimveliso ezintsha zonyango, ukhuseleko kunye nokhathalelo lwesikhumba.
Iimveliso zayo eziphambili zibandakanya i-Ameluz®, iyeza elimiselweyo lokunyanga umhlaza wesikhumba ongeyo-melanoma kunye nabandulelayo. I-Ameluz® iye yathengiswa kwi-EU ukususela ngo-2012 nakwi-USA ukususela ngoMeyi 2016. EYurophu, inkampani iphinda ithengise i-Belixos® dermocosmetic series, imveliso ekhethekileyo yokunyamekela kwesikhumba esonakele. I-Biofrontera yenye yamaJamani ambalwa Inkampani yamayeza ukufumana imvume yaseYurophu kunye ne-US malunga neyeza eliphuhliswe ngaphakathi. Iqela le-Biofrontera lasekwa kwi-1997 kwaye libhalwe kwi-Frankfurt Stock Exchange (i-Prime Standard).
Vita 34 Ag Na
Yasekwa eLeipzig ngo-1997 njengegazi lokuqala labucala le-umbilical cord ibhanki eYurophu, i-Vita 34 ngumthengisi ogcweleyo we-cryo-preservation kwaye ibonelela nge-logistics yokuqokelela igazi, ukulungiswa kunye nokugcinwa kweeseli ze-stem kwi-umbilical cord yegazi kunye nezicubu.
Iiseli zestem zingumthombo oxabisekileyo wezinto zonyango lweeseli zonyango. Zigcinwa ziphila kumaqondo obushushu amalunga ne-180 degrees Celsius ukuze zikwazi ukuzisebenzisa ngaphakathi kwendawo yonyango, xa zifuneka. Ngaphezulu kwabathengi be-230.000 abavela eJamani kunye namanye amazwe angama-20 sele evule iidiphozithi ze-stem cell kunye ne-Vita 34, ngaloo ndlela ebonelela ngempilo yabantwana babo.
Heidelberg Pharma Ag
I-Heidelberg Pharma AG yinkampani ye-biopharmaceutical esebenza kwinkalo ye-oncology. Inkampani igxile ekuphuhliseni i-Antibody Drug Conjugates (ADCs) yonyango lwezifo ze-oncological. I-Heidelberg Pharma's ebizwa ngokuba yi-ATACs zii-ADCs ezisekelwe kubuchwephesha be-ATAC obusebenzisa i-Amanitin njengesithako esisebenzayo. Indlela yebhayoloji yokusebenza yetyhefu ye-Amanitin imele umgaqo omtsha wonyango.
Eli qonga lobunikazi lisetyenziselwa ukuphuhlisa i-ATACs yonyango yeNkampani kunye nentsebenziswano yomntu wesithathu ukudala iindidi zabaviwa be-ATAC. Umgqatswa okhokelayo we-HDP-101 yi-BCMA-ATAC ye-myeloma eninzi. Abanye abagqatswa bophuhliso lwangaphambi kweklinikhi yi-HDP-102, i-CD37 ATAC ye-Non-Hodgkin lymphoma kunye ne-HDP-103, i-PSMA ATAC yomhlaza wedlala lesinyi.
Inkampani kunye nenkxaso yayo iHeidelberg Pharma Research GmbH izinze eLadenburg kufutshane neHeidelberg eJamani. Yasekwa ngoSeptemba 1997 njengeWilex Biotechnology GmbH eMunich kwaye yatshintshwa yaba yiWILEX AG ngo-2000. Ngo-2011, i-subsidiary ye-Heidelberg Pharma Research GmbH yafunyanwa kwaye emva kohlengahlengiso, i-ofisi ebhalisiweyo ye-WILEX AG yasuswa eMunich yaya eLadenburg kwaye Igama leNkampani latshintshwa laba yi-Heidelberg Pharma AG.
I-subsidiary ye-Heidelberg Pharma GmbH ngoku ibizwa ngokuba yi-Heidelberg Pharma Research GmbH. I-Heidelberg Pharma AG idweliswe kwi-Frankfurt Stock Exchange kwi-Regulated Market / Prime Standard.
